MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517065494 A) filed by Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, Germany, on July 9, for 'glp1/gip/npy2 receptor triple agonists.'
Inventor(s) include Haebel, Peter Wilhelm; Augustin, Robert; Madsen, Charlotte Stahl; Murray, Anthony; and Teufel, Daniel Paul.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "Hybrid polypeptides that agonize the GIP, GLP-1 and neuropeptide Y2 (NPY2) receptors and their medical use in the treatment of a variety of diseases, conditions or disorders, such as obesity, diabetes, and/or NASH are disclosed. The polypeptides have the general structure Z1-Z2-Z3, wherein Z1 is a hybrid polypeptide providing GIPR and GLP1R agonism, Z2 is a linker, and Z3 is a polypeptide providing hY2R agonism."
The patent application was internationally filed on Dec. 20, 2023, under International application No.PCT/EP2023/086825.
Disclaimer: Curated by HT Syndication.
